title: Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials.
abstract: Repetitive behavior is a core feature of autism spectrum disorder. We used 8-week data from two federally funded, multi-site, randomized trials with risperidone conducted by the Research Units on Pediatric Psychopharmacology Autism Network to evaluate the sensitivity of the Children's Yale-Brown Obsessive Compulsive Scale modified for autism spectrum disorder to detect change with treatment. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. In Study 2, 49 subjects received risperidone only and 75 subjects received risperidone plus parent training. The combined sample consisted of 187 boys and 38 girls (aged 4-17 years). At the medication-free baseline, the internal consistency on the Children's Yale-Brown Obsessive Compulsive Scale modified for autism spectrum disorder total score was excellent (Cronbach's alpha = 0.84) and the mean scores were similar across the four groups. Compared to placebo in Study 1, all three active treatment groups showed significant improvement (effect sizes: 0.74-0.88). There were no differences between active treatment groups. These results indicate that the Children's Yale-Brown Obsessive Compulsive Scale modified for autism spectrum disorder has acceptable test-retest as evidenced by the medium to high correlations in the placebo group and demonstrated sensitivity to change with treatment.
authors.affiliation: Emory University, USA lawrence.scahill@emory.edu.
authors.forename: Lawrence
authors.initials: L
authors.lastname: Scahill
authors.affiliation: Yale University, USA.
authors.forename: Denis G
authors.initials: DG
authors.lastname: Sukhodolsky
authors.affiliation: Brigham Young University, University of Washington, USA.
authors.forename: Emily
authors.initials: E
authors.lastname: Anderberg
authors.affiliation: Case Western Reserve University, USA.
authors.forename: Anastasia
authors.initials: A
authors.lastname: Dimitropoulos
authors.affiliation: Yale University, USA.
authors.forename: James
authors.initials: J
authors.lastname: Dziura
authors.affiliation: The Ohio State University, USA.
authors.forename: Michael G
authors.initials: MG
authors.lastname: Aman
authors.affiliation: University of California, Los Angeles, USA.
authors.forename: James
authors.initials: J
authors.lastname: McCracken
authors.affiliation: Johns Hopkins University, USA.
authors.forename: Elaine
authors.initials: E
authors.lastname: Tierney
authors.affiliation: Kings College London, UK.
authors.forename: Victoria
authors.initials: V
authors.lastname: Hallett
authors.affiliation: Yale University, USA.
authors.forename: Karol
authors.initials: K
authors.lastname: Katz
authors.affiliation: National Institute of Mental Health, Child and Adolescent Treatment and Preventive Interventions Research Branch, USA.
authors.forename: Benedetto
authors.initials: B
authors.lastname: Vitiello
authors.affiliation: Massachusetts General Hospital, USA.
authors.forename: Christopher
authors.initials: C
authors.lastname: McDougle
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000067877:Autism Spectrum Disorder / Q000150:complications*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006266:Health Education; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D010290:Parents; D011569:Psychiatric Status Rating Scales / Q000592:standards*; D018967:Risperidone / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone
keywords: autism spectrum disorder; clinical trials; outcome measurement; repetitive behavior; risperidone